Log in to search using one of your social media accounts:

 

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar
NEW YORK (Reuters) - Daiichi Sankyo on Tuesday said it has agreed to pay up to $300 million to settle some 2,300 U.S. cases accusing the Japanese drugmaker of failing to warn that its blood pressure medication Benicar can cause gastrointestinal illness. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Jubilant Life gets USFDA nod for hypertension drug
In a BSE filing, the company said it has received abbreviated new drug application (ANDA) final approval for olmesartan medoxomil tablets - 5 mg, 20 mg, and 40 mg. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 25, 2017 Category: Pharmaceuticals Source Type: news

Alembic Pharma gets USFDA nod for anti-hypertension drugs
The approved products are therapeutically equivalent to the reference listed drug products Benicar and Benicar HCT of Daiichi Sankyo, which is used for the treatment of hypertension, it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 25, 2017 Category: Pharmaceuticals Source Type: news

Tribenzor (Olmesartan Medoxomil Amlodipine Hydrochlorothiazide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 30, 2017 Category: Drugs & Pharmacology Source Type: news

Azor (Amlodipine and Olmesartan Medoxomil Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 28, 2016 Category: Drugs & Pharmacology Source Type: news

Lupin gets USFDA nod for hypertension treatment drug in US
Olmesartan medoximil tablets, generic version of Daiichi Sankyo's Benicar, are indicated for the treatment of hypertension, along with other anti-hypertensive agents. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 26, 2016 Category: Pharmaceuticals Source Type: news

Teva receives approval for generic Tribenzor in US
Teva Pharmaceutical Industries has secured approval for generic Tribenzor (olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets in the US and is in the last stages of launch preparation. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 9, 2016 Category: Pharmaceuticals Source Type: news

Ajanta Pharma launches BP lowering tablets in US
Ajanta Pharma's Amlodipine + Olmesartan Medoxomil tablets are a generic version of Daiichi Sankyo Inc's Azor tablets ​ (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 2, 2016 Category: Pharmaceuticals Source Type: news

3 Drugs with the Most Severe Side Effects
Image Source Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever. The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 19, 2016 Category: Consumer Health News Source Type: news

Benicar HCT (Olmesartan Medoxomil-Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 26, 2016 Category: Drugs & Pharmacology Source Type: news

Benicar (Olmesartan Medoxomil) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 26, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Safety Review Update of Benicar (olmesartan) and cardiovascular events
This safety review update is in follow-up to the FDA Drug Safety Communication:Ongoing Safety Review of Benicar (olmesartan) and cardiovascular events on 6/11/2010. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 7, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil
The U.S. Food and Drug Administration (FDA) is warning that the blood pressure drug olmesartan medoxomil (marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics) can cause intestinal problems known as sprue-like enteropathy. FDA has approved changes to the labels of these drugs to include this concern. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2016 Category: Drugs & Pharmacology Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: FDA aprueba cambios en la etiqueta para problemas intestinales (enteropatía similar a esprue) asociada con el medicamento olmesartán medoxomil para la presión alta
El 3 de julio, 2013, La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) advirtió que el medicamento para la presión alta olmesartán medoxomil (comercializado como Benicar, Benicar HCT, Azor, Tribenzor y genéricos) ha sido asociado con problemas intestinales conocidos como enteropatía similar a esprue, y la agencia ha aprobado cambios en las etiquetas de estos medicamentos que mencionan esta inquietud. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news

U.S. top court allows Apotex to pursue generic version of Daiichi drug
WASHINGTON (Reuters) - The U.S. Supreme Court on Monday rejected appeals by Daiichi Sankyo Inc and Mylan Pharmaceuticals Inc seeking to stop Apotex Inc from trying to introduce a generic version of Benicar, a drug for treating hypertension. (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

New York Law Firm States That the FDA Announces Health Risks Involved...
New York Law Firm States That the FDA Announces Health Risks Involved with Patients Who Have Taken Benicar(PRWeb August 20, 2014)Read the full story at http://www.prweb.com/releases/2014/08/prweb12098612.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 21, 2014 Category: Pharmaceuticals Source Type: news

FDA Once Again Reaches Conclusions At Odds With Its Own Staff
Once again the FDA has reached a conclusion that is directly opposed by some of its own scientists.  Last month the FDA affirmed the safety of olmesartan, a popular blood pressure lowering drug (sold as Benicar and other names). But that reassuring view is not shared by the  FDA scientists who performed the study that provided the basis for the review. And now outside experts are also raising concerns about the drug. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 14, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

FDA Alert Warns of Serious Intestinal Problems from Benicar, Azor and...
Have you experienced intestinal problems after taking Benicar, Azor or Tribenzor? There are current lawsuits being filed on behalf of victims.(PRWeb July 08, 2014)Read the full story at http://www.prweb.com/releases/Intestinal-Problems/Benicar-Azor-Tribenzor/prweb12001069.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 8, 2014 Category: Pharmaceuticals Source Type: news

FDA Ends Olmesartan Safety Review, But...
The FDA announced on Tuesday that it had completed its safety review of the antihypertensive drug olmesartan (sold as Benicar and other names). The investigation was initiated in 2010 when results from the ROADMAP trial showed that patients with type 2 diabetes taking olmesartan had an increased risk of cardiovascular death. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 25, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Affordrx.com Now Makes Benicar and Other Hypertension Prescriptions...
AffordRx provides savings on beta blockers and thousands of medications.(PRWeb May 31, 2014)Read the full story at http://www.prweb.com/releases/2014/05/prweb11885958.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 1, 2014 Category: Pharmaceuticals Source Type: news

Levin, Papantonio Law Firm Files Benicar Lawsuit
The Levin, Papantonio law firm has filed a Benicar lawsuit on behalf of a Texas man who suffered sprue-like enteropathy while using the blood pressure medication Benicar.(PRWeb March 18, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11659164.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 18, 2014 Category: Pharmaceuticals Source Type: news

MedicationDiscountCard.com Helps Combat the Silent Killer with Benicar...
Benicar prescription discount cards help save patients 10-75% on high blood pressure medication.(PRWeb January 22, 2014)Read the full story at http://www.prweb.com/releases/Benicar/Coupon/prweb11507601.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 22, 2014 Category: Pharmaceuticals Source Type: news

Drug Injury Attorney Jeffrey D. DeCarlo Comments on FDA Warning About...
The attorney at the Law Offices of Jeffrey D. DeCarlo discusses steps patients who have been harmed by pharmaceutical products can take to protect their rights.(PRWeb December 19, 2013)Read the full story at http://www.prweb.com/releases/benicar-health-problems/lawyer-fl/prweb11408865.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 20, 2013 Category: Pharmaceuticals Source Type: news

Flood Law Group to Sponsor BenicarLawsuits.org
The personal injury lawyers at Flood Law Group announce the release of the new website, BenicarLawsuits.org, an online resource dedicated to educating consumers about the risks associated with the...(PRWeb July 26, 2013)Read the full story at http://www.prweb.com/releases/benicar-lawsuits/website/prweb10966557.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 27, 2013 Category: Pharmaceuticals Source Type: news

FDA Adds GI Warning to Benicar Label
WASHINGTON (MedPage Today) -- The FDA ordered the maker of the blood pressure drug olmesartan (Benicar) to add a warning about risk of the intestinal condition known as sprue-like enteropathy to the drug's label. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 3, 2013 Category: Cardiology Source Type: news

FDA warns on Daiichi Sankyo blood pressure drugs
(Reuters) - U.S. health regulators warned on Wednesday that Daiichi Sankyo Inc's blood pressure drugs Benicar, Benicar HCT, Azor and Tribenzor can cause severe, chronic diarrhea and substantial weight loss, sometimes requiring hospitalization. (Source: Reuters: Health)
Source: Reuters: Health - July 3, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy)
Enteropathy may develop months to years after starting olmesartan, and sometimes requires hospitalization. (Source: FDA MedWatch)
Source: FDA MedWatch - July 3, 2013 Category: American Health Source Type: news